Nextech Invest Ltd. — 13F Holdings & Portfolio
CIK 1595430 · latest 13F-HR filed 2026-08-14
Nextech Invest Ltd. manages $2.11B in 13F-reported U.S. long-equity assets across 16 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RVMD (67.55%), PBLS (6.06%), RLAY (6.02%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions and exited 4; 7 existing positions rose in reported value and 4 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 98%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 27, 2026.
ZURICH 8001
Switzerland
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| HEADLAND HOLDING AG Control | DIRECT OWNER since Mar 2018 | 50–75% | Foreign Entity |
| NEXTECH HOLDING AG Control | DIRECT OWNER since Mar 2018 | 10–25% | Foreign Entity |
| POTHULA, KANISHKA, RAM Control | DIRECT OWNER since Mar 2023 | 5–10% | Individual |
| SCHROEDER, THILO, NMN Control | MANAGING PARTNER since Mar 2018 | Less than 5% | Individual |
| SGOBBO, ROCCO, JOSEPH Control | MANAGING PARTNER AND CHIEF OPERATING OFFICER since Mar 2018 | Less than 5% | Individual |
| STATION STREET HOLDINGS AG Control | DIRECT OWNER since Mar 2018 | 10–25% | Foreign Entity |
| WEIBEL, MARCO, CHRISTIAN Control | CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER since Mar 2018 | Less than 5% | Individual |
| SCHEIDEGGER, ALFRED, NMN Control Indirect owner via NEXTECH HOLDING AG | OWNER since Mar 2018 | 75% or more | Individual |
| SCHROEDER, THILO, NMN Control Indirect owner via HEADLAND HOLDING AG | OWNER since Mar 2018 | 75% or more | Individual |
| SGOBBO, ROCCO, JOSEPH Control Indirect owner via STATION STREET HOLDINGS AG | OWNER since Mar 2018 | 75% or more | Individual |
Ownership & leadership changes · 3 filings with changes since Aug 25, 2022
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedLOVEN, JAKOB, HENRIK · PARTNER · Less than 5% · control person · listed since Mar 2018
- Listed againSCHEIDEGGER, ALFRED, NMN · OWNER · 75% or more · indirect via NEXTECH HOLDING AG · control person
- No longer listedCLARENDON CAPITAL AG · DIRECT OWNER · 25–50% · control person · listed since Mar 2018
- No longer listedLOVEN, JAKOB, HENRIK · OWNER · 75% or more · indirect via CLARENDON CAPITAL AG · control person · listed since Mar 2018
- No longer listedSCHEIDEGGER, ALFRED, NMN · OWNER · 75% or more · indirect via NEXTECH HOLDING AG · control person · listed since Mar 2018
- No longer listedSCHEIDEGGER, ALFRED, NMN · MANAGING PARTNER · Less than 5% · control person · listed since Mar 2018
- AddedPOTHULA, KANISHKA, RAM · DIRECT OWNER · 5–10% · control person
- ChangedHEADLAND HOLDING AG · ownership 25–50% → 50–75%
- ChangedLOVEN, JAKOB, HENRIK · title MANAGING PARTNER → PARTNER
- ChangedNEXTECH HOLDING AG · ownership 25–50% → 10–25%
- ChangedSGOBBO, ROCCO, JOSEPH · now a control person
- ListedCLARENDON CAPITAL AG · DIRECT OWNER · 25–50% · control person
- ListedHEADLAND HOLDING AG · DIRECT OWNER · 25–50% · control person
- ListedLOVEN, JAKOB, HENRIK · MANAGING PARTNER · Less than 5% · control person
- ListedLOVEN, JAKOB, HENRIK · OWNER · 75% or more · indirect via CLARENDON CAPITAL AG · control person
- ListedNEXTECH HOLDING AG · DIRECT OWNER · 25–50% · control person
- ListedSCHEIDEGGER, ALFRED, NMN · OWNER · 75% or more · indirect via NEXTECH HOLDING AG · control person
- ListedSCHEIDEGGER, ALFRED, NMN · MANAGING PARTNER · Less than 5% · control person
- ListedSCHROEDER, THILO, NMN · MANAGING PARTNER · Less than 5% · control person
- ListedSCHROEDER, THILO, NMN · OWNER · 75% or more · indirect via HEADLAND HOLDING AG · control person
- ListedSGOBBO, ROCCO, JOSEPH · MANAGING PARTNER AND CHIEF OPERATING OFFICER · Less than 5%
- ListedSGOBBO, ROCCO, JOSEPH · OWNER · 75% or more · indirect via STATION STREET HOLDINGS AG · control person
- ListedSTATION STREET HOLDINGS AG · DIRECT OWNER · 10–25% · control person
- ListedWEIBEL, MARCO, CHRISTIAN · CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- REVOLUTION MEDICINES INC$684.3M +92.6%
- RELAY THERAPEUTICS INC$71.8M +130.6%
- ALUMIS INC$21.6M +27.7%
- MONTE ROSA THERAPEUTICS INC$13.4M +268.1%
- ARVINAS INC$11.4M +199.4%
Top Trims
- TYRA BIOSCIENCES INC-$41.8M -26.9%
- CONTEXT THERAPEUTICS INC-$15.3M -78.9%
- ORIC PHARMACEUTICALS INC-$13.2M -14.5%
- CYTOMX THERAPEUTICS INC.-$4.2M -20.2%
Exited Positions
- TANGO THERAPEUTICS INC$152.0M
- CULLINAN THERAPEUTICS INC$16.2M
- ENGENE HOLDINGS INC$15.8M
- ARS PHARMACEUTICALS INC$4.9M
Nextech Invest Ltd. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $1.42B | 67.55% | 7,601,087 | SH |
| 2 | PARABILIS MEDICINES INC | PBLS | 698955101 | $127.6M | 6.06% | 4,663,176 | SH |
| 3 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $126.8M | 6.02% | 6,776,506 | SH |
| 4 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $113.5M | 5.39% | 3,553,585 | SH |
| 5 | ALUMIS INC | ALMS | 022307102 | $99.6M | 4.73% | 3,540,998 | SH |
| 6 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $77.6M | 3.68% | 7,162,637 | SH |
| 7 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $32.0M | 1.52% | 278,896 | SH |
| 8 | ZYMEWORKS INC | ZYME | 98985Y108 | $29.1M | 1.38% | 1,113,946 | SH |
| 9 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $18.4M | 0.87% | 761,153 | SH |
| 10 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $16.7M | 0.79% | 4,449,932 | SH |
| 11 | AVALO THERAPEUTICS INC | ARVN | 04335A105 | $14.2M | 0.67% | 766,000 | SH |
| 12 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $10.5M | 0.50% | 952,400 | SH |
| 13 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $6.7M | 0.32% | 450,000 | SH |
| 14 | CONTEXT THERAPEUTICS INC | CNTX | 21077P108 | $4.1M | 0.20% | 7,419,355 | SH |
| 15 | ENGENE THERAPEUTICS INC | ENGN | 29286X101 | $4.0M | 0.19% | 2,324,943 | SH |
| 16 | ARVINAS INC | ARVN | 04335A105 | $3.0M | 0.14% | 356,713 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $2.11B | 16 | 0001595430-26-000010 |
| 2026-03-31 | 2026-05-15 | $1.42B | 17 | 0001595430-26-000005 |
| 2025-12-31 | 2026-02-17 | $1.03B | 16 | 0001595430-26-000002 |
| 2025-09-30 | 2025-11-14 | $657.0M | 15 | 0001595430-25-000007 |
ZURICH 8001